Growth Hormone Secretagogues · Research deep dive
Ipamorelin: the cited literature
Every study referenced in the Ipamorelin monograph, with plain-language context, PubMed links to read each paper yourself, and how the compound appears in the dosing literature.
How this compound is studied
Across the dosing literature, Ipamorelin is studied at 200 mcg – 300 mcg per administration, typically one to three times daily. The reference walkthrough below maps each citation to what it actually showed.
References covered
Ipamorelin, the first selective GH secretagogue
Eur. J. Endocrinol., 1998
The full walkthrough is for subscribers
Unlock the evidence grading, what each study actually found, how the trials dosed it, reported safety signals, open questions, and PubMed links for Ipamorelin.